Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study

Date

09 Oct 2016

Session

Poster display

Presenters

Melissa Bersanelli

Citation

Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373

Authors

M. Bersanelli1, F. Maines2, G. Facchini3, F. Gelsomino4, F. Zustovich5, M. Santoni6, E. Verri7, U. De Giorgi8, C. Masini9, F. Morelli10, M.G. Vitale11, T. Sava12, G. Prati13, C. Librici14, A.P. Fraccon15, G. Fornarini16, M. Maruzzo17, F. Leonardi1, O. Caffo2, S. Buti1

Author affiliations

  • 1 Medical Oncology, University Hospital of Parma, 43126 - Parma/IT
  • 2 Medical Oncology, Ospedale Santa Chiara, Trento/IT
  • 3 Medical Oncology, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, Napoli/IT
  • 4 Medical Oncology, Policlinico S. Orsola-Malpighi, 401238 - Bologna/IT
  • 5 Medical Oncology, Ospedale di Belluno, 32100 - Belluno/IT
  • 6 Medical Oncology, AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, 60020 - Ancona/IT
  • 7 Medical Oncology, Istituto Europeo di Oncologia, 20141 - Milano/IT
  • 8 Medical Oncology, Istituto Tumori della Romagna I.R.S.T., Meldola/IT
  • 9 Medical Oncology, Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, 42123 - Reggio Emilia/IT
  • 10 Medical Oncology, Ospedale Casa Sollievo della Sofferenza, 71013 - San Giovanni Rotondo/IT
  • 11 Medical Oncology, Azienda Ospedaliera di Rilievo Nazionale "Antonio Cardarelli"-AORN A. Cardarelli, Napoli/IT
  • 12 Medical Oncology, Azienda Ospedaliera Universitaria Integrata Verona-"Borgo Trento", Verona/IT
  • 13 Medical Oncology, Hospital of Guastalla, Guastalla/IT
  • 14 Medical Oncology, Ospedali Riuniti Villa Sofia – Cervello Hospital, Palermo/IT
  • 15 Oncologia, Casa di Cura Dott. Pederzoli, 37029 - Peschiera Del Garda/IT
  • 16 Medical Oncology, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova/IT
  • 17 Oncologia Medica 1, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
More

Resources

Abstract 2590

Background

Pazopanib is a standard first line treatment for metastatic clear cell renal cell carcinoma (RCC). Very few data on its activity in non-clear cell RCC (nccRCC) are currently available in the literature. We retrospectively analyzed efficacy and toxicity of Pazopanib in an Italian multicenter cohort of nccRCC patients.

Methods

Records from nccRCC patients treated with first line Pazopanib were reviewed and collected. Response rate (RR), progression free survival (PFS), and overall survival (OS) were evaluated in this cohort. Univariate analysis were conducted to correlate clinicopathological factors with outcome. Descriptive analysis of patients and diseases characteristics were also performed.

Results

Between 2010 and 2015, 37 patients with nccRCC were treated with Pazopanib as first line therapy at 17 Italian centers. 24% had chromophobe histology, 51% papillary, 22% unclassified and 3% had Xp11 translocation. Motzer and Heng risk were good in 22% and 24%, intermediate in 68% and 49% and poor in 10% and 22% of patients respectively. 76% had nephrectomy. 57% had ECOG performance status (PS) = 0, 27% PS = 1 and 16% PS = 2-3. 22% had a basal neutrophil to lymphocyte ratio (NLR) ≥ 3. Dose reductions/interruptions of Pazopanib for toxicity were required in 46% of cases; G3-4 toxicity occurred in 32% of patients, G1-2 in 89%. 81% achieved clinical benefit (partial response or stable disease), while 16% had disease progression as best response. Median PFS (38% censored) and OS (46% censored) were 15.9 [95%CI 5.9–25.8] and 17.3 [95%CI 11.5-23.0] months, respectively. At the univariate analysis, factors associated with PFS were nephrectomy (p = 0.02), Motzer score (p 

Conclusions

In nccRCC patients, treatment with Pazopanib demonstrated to be effective and feasible, despite dose reductions often required for toxicity in this population.

Clinical trial identification

not applicable

Legal entity responsible for the study

Santa Chiara Hospital, Trento.

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings